Drug Profile
Endometriosis therapy - Bayer/Evotec SE
Alternative Names: Second endometriosis candidate - Bayer/Evotec SELatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Bayer; Evotec AG
- Developer Bayer; Evotec SE
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Endometriosis